EUVIMEDEUVIMED entdecken
Open Access

Thermoresponsive Polymeric Hydromorphone Prodrug Provides Sustained Local Analgesia without Apparent Adverse Effects

Zhenshan Jia, Xin Wei, Ningrong Chen, Xiaoke Xu, Gang Zhao, Xin Fu, Hanjun Wang, Mary B Goldring, Steven R Goldring, Dong Wang iD

Molecular Pharmaceutics · 01.04.2024 · 21 (4) · 1838-1847

DOI: 10.1021/acs.molpharmaceut.3c01133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 27.02.2024. Verfasst von Zhenshan Jia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States. Hauptthemen laut MEDLINE: Prodrugs, Analgesia, Drug-Related Side Effects and Adverse Reactions, Osteoarthritis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIDA NIH HHS, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The extensive use of opioids for chronic pain management has contributed significantly to the current opioid epidemic. While many alternative nonopioid analgesics are available, opioids remain the most potent analgesics for moderate to severe pain management. In addition to the implementation of multimodal analgesia, there is a pressing need for the development of more effective and safer opioids. In this study, we developed a thermoresponsive N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-based hydromorphone (HMP) prodrug (ProGel-HMP, HMP content = 16.2 wt %, in base form). The aqueous solution of ProGel-HMP was free-flowing at 4 °C but became a hydrogel when the temperature was raised to ≥37 °C, allowing sustained local retention when administered in vivo. When tested in the destabilization of the medial meniscus (DMM) mouse model of osteoarthritis (OA), ProGel-HMP was retained after intra-articular injection in the OA knee joint for at least 2 weeks postinjection, with low extra-articular distribution. ProGel-HMP was not detected in the central nervous system (CNS). A single dose of ProGel-HMP produced rapid and sustained joint pain resolution for greater than 14 days when compared to saline and dose-equivalent HMP controls, likely mediated through peripheral μ-opioid receptors in the knee joint. Systemic analgesia effect was absent in the DMM mice treated with ProGel-HMP, as evident in the lack of difference in tail flick response between the ProGel-HMP-treated mice and the controls (i.e., Healthy, Saline, and Sham). Repeated dosing of ProGel-HMP did not induce tolerance. Collectively, these data support the further development of ProGel-HMP as a potent, safe, long-acting and nonaddictive analgesic for better clinical pain management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsAnalgesiaDrug-Related Side Effects and Adverse ReactionsOsteoarthritisMiceAnimalsHydromorphonePain ManagementPainAnalgesics, OpioidAnalgesics

Stichwörter der Autor:innen

HPMAProGelhydromorphoneopioidsosteoarthritispainprodrugthermoresponsive

Substanzen

HydromorphoneProdrugsAnalgesics, OpioidAnalgesics

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198-6125, United States.
  • Ensign Pharmaceutical, Omaha, Nebraska 68106, United States.
  • Department of Anesthesiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198-4455, United States.
  • Hospital for Special Surgery, New York, New York 10021, United States.
  • Department of Orthopaedic and Rehabilitation, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198-5640, United States.

ORCID-Profile: Dong Wang

Förderung

  • NIAMS NIH HHS
  • NIDA NIH HHS
  • China Scholarship Council
  • National Institutes of Health

Zitieren

APA

Jia, Z., Wei, X., Chen, N., Xu, X., Zhao, G., Fu, X., Wang, H., Goldring, M. B., Goldring, S. R., & Wang, D. (2024). Thermoresponsive Polymeric Hydromorphone Prodrug Provides Sustained Local Analgesia without Apparent Adverse Effects. Molecular Pharmaceutics, 21(4), 1838-1847. https://doi.org/10.1021/acs.molpharmaceut.3c01133

Vancouver

Jia Z, Wei X, Chen N, Xu X, Zhao G, Fu X, et al. Thermoresponsive Polymeric Hydromorphone Prodrug Provides Sustained Local Analgesia without Apparent Adverse Effects. Molecular Pharmaceutics. 2024;21(4):1838-1847. doi:10.1021/acs.molpharmaceut.3c01133

BibTeX
@article{Jia2024,
  author = {Jia, Zhenshan and Wei, Xin and Chen, Ningrong and Xu, Xiaoke and Zhao, Gang and Fu, Xin and Wang, Hanjun and Goldring, Mary B and Goldring, Steven R and Wang, Dong},
  title = {Thermoresponsive Polymeric Hydromorphone Prodrug Provides Sustained Local Analgesia without Apparent Adverse Effects},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {4},
  pages = {1838--1847},
  doi = {10.1021/acs.molpharmaceut.3c01133}
}
Kostenlos starten →